These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
302 related articles for article (PubMed ID: 4208807)
21. Effects of antidepressant treatment with clomipramine on hormonal responses to thyrotropin-releasing hormone and insulin-induced hypoglycemia: implications for the "monoamine-hypothesis". Langer G; Karobath M; Sieghart W; Aschauer H; Placheta P; Spona J Pharmacopsychiatria; 1981 May; 14(3):100-6. PubMed ID: 6789342 [TBL] [Abstract][Full Text] [Related]
22. Effect of somatostatin in patients with acromegaly: suppression of growth hormone, prolactin, insulin and glucose levels. Yen SS; Siler TM; DeVane GW N Engl J Med; 1974 Apr; 290(17):935-8. PubMed ID: 4593614 [No Abstract] [Full Text] [Related]
23. Growth hormone and changes in the secretion of thyrotropic hormone after thyrotropin-releasing hormone (TRH): ineffectiveness of dopaminergic stimulation. Felt V; Nedvídková J Endokrinologie; 1982 Oct; 80(2):201-6. PubMed ID: 6819130 [No Abstract] [Full Text] [Related]
24. Regulation of growth hormone and prolactin secretion in patients with acromegaly and-or excessive prolactin secretion. Cryer PE; Jacobs LS; Daughaday WH Mt Sinai J Med; 1973; 40(3):402-13. PubMed ID: 4197309 [No Abstract] [Full Text] [Related]
25. [Growth hormone secretion in relation to changes in thyrotropic hormone after thyroliberin in patients with acromegaly and dopaminergic stimulation (author's transl)]. Felt V; Nedvídková J Cas Lek Cesk; 1982 Apr; 121(16):489-93. PubMed ID: 6807547 [No Abstract] [Full Text] [Related]
26. Long-term treatment of acromegaly with Sandostatin (SMS 201-995). Normalization of most anomalous growth hormone responses. Pieters GF; van Liessum PA; Smals AG; van Gennep JA; Benraad TJ; Kloppenborg PW Acta Endocrinol Suppl (Copenh); 1987; 286():9-18. PubMed ID: 2892339 [TBL] [Abstract][Full Text] [Related]
37. Plasma growth hormone and prolactin responses to TRH and arginine given before and during bromocriptine therapy to patients with acromegaly. Hanew K; Sasaki A; Mouri T; Yoshinaga K Acta Endocrinol (Copenh); 1980 Nov; 95(3):298-307. PubMed ID: 6776756 [No Abstract] [Full Text] [Related]
38. Dynamic evaluation of growth hormone (GH) and prolactin (hPRL) secretion in active acromegaly with high and low GH output. Tolis G; Kovacs L; Friesen H; Martin JB Acta Endocrinol (Copenh); 1975 Feb; 78(2):251-7. PubMed ID: 803748 [TBL] [Abstract][Full Text] [Related]
39. The pituitary-thyroid axis in acromegaly. Eskildsen PC; Kruse A; Kirkegaard C Horm Metab Res; 1988 Dec; 20(12):755-7. PubMed ID: 3146541 [TBL] [Abstract][Full Text] [Related]
40. The effect of 3,5,3'-triiodothyronine or thyrotropin-releasing hormone on pituitary hormone responses to arginine infusions in hypothyroid patients. LaMantia R; Spaulding S; Reese P J Clin Endocrinol Metab; 1981 Jan; 52(1):86-90. PubMed ID: 6778894 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]